ZYY-B-2, a novel ALK inhibitor, overcomes resistance to ceritinib by inhibiting P-gp function and induces apoptosis through mitochondrial pathway in ceritinib-resistant H2228 cells-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

ZYY-B-2, a novel ALK inhibitor, overcomes resistance to ceritinib by inhibiting P-gp function and induces apoptosis through mitochondrial pathway in ceritinib-resistant H2228 cells

Published:2023-07 Issue: Volume:379 Page:110516
ISSN:0009-2797
Container-title:Chemico-Biological Interactions
language:en
Short-container-title:Chemico-Biological Interactions

Author:

Gao Ying,Liu Tong,Liu Jingang,Yang Yuying,Sun Keyan,Li Zengqiang,Zhai Xin,Zuo Daiying^ORCID

Funder

Liaoning Provincial Natural Science Foundation

Publisher

Elsevier BV

Subject

Toxicology,General Medicine

Reference45 articles.

1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA A Cancer J. Clin.,2021

2. Cancer treatment and survivorship statistics;Miller;CA A Cancer J. Clin.,2022

3. The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC);Golding;Mol. Cancer,2018

4. Interpretation of ceritinib clinical trial results and future combination therapy strategies for ALK-rearranged NSCLC;Blakely;Expert Rev. Anticancer Ther.,2019

5. Understanding and targeting resistance mechanisms in NSCLC;Rotow;Nat. Rev. Cancer,2017

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP